Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
29 hedge funds and large institutions have $1.25M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 12 closing their positions.
583% more call options, than puts
Call options by funds: $41K | Put options by funds: $6K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 34 → 29 (-5)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
48% less capital invested
Capital invested by funds: $2.41M → $1.25M (-$1.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.8K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$23.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$15K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.42K |
| 5 |
HF
HRT Financial
New York
|
+$5.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$255K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$214K |
| 3 |
Morgan Stanley
New York
|
-$163K |
| 4 |
VF
Virtu Financial
New York
|
-$63.1K |
| 5 |
State Street
Boston,
Massachusetts
|
-$51K |
NBRV Hedge Fund Activity: Q1 2022 in Review
29 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q1 2022, worth a combined $1.25M — down 48% from $2.41M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NBRV and 8 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, adding an estimated $24.8K. The largest seller was Frazier Management, exiting entirely with an estimated $255K sold.
- 29 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q1 2022, down from 34 in Q4 2021.
- Funds reported $1.25M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q1 2022, down 48% quarter-over-quarter.
- 8 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q1 2022 and 12 closed out, a net change of -4 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q1 2022 was Susquehanna International Group, an estimated $24.8K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q1 2022 was Frazier Management, an estimated $255K sold.
Based on aggregated 13F filings for Q1 2022.